
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company has completed enrollment in its Phase 2 study of PR022, Realm’s first-in-class topical […]